After more than three decades, schizophrenia patients have a new treatment option. The US FDA has approved a drug, known as ...

Cobenfy is the first FDA-approved antipsychotic that targets cholinergic receptors instead of dopamine receptors.

Available antipsychotic treatments work by blocking dopamine receptors. The new drug, Cobenfy, takes a different approach.

The approval comes less than a year Bristol Myers Squibb paid $14 billion to acquire the developer of the drug, Karuna ...

As they both campaign for re-election, the premiers of British Columbia and New Brunswick appear to agree on one ...

A BMJ investigation found seven of the eight doctors appointed by the US Food & Drug Administration (FDA) to review donanemab ...

US poised to approve KarXT as new antipsychotic treatment for disorder, which could offer reduced side-effects ...

There hasn’t been a new class of drugs approved to help smokers quit since Pfizer's Chantix reached the market nearly two ...

Barry O’Keefe did not want his son Andrew to go into show business. The titan of Australian justice – he was a judge, mayor ...

Roddy Collins, Kenneth Egan and Philly McMahon are among the sports stars who have supported the work done in Finglas-based ...

The FDA is poised to issue a decision soon on KarXT, a potential first-in-class antipsychotic for schizophrenia. What should ...